Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
80 hedge funds and large institutions have $301M invested in Revance Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 19 reducing their positions, and 27 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less funds holding
Funds holding: 98 → 80 (-18)
46% less capital invested
Capital invested by funds: $556M → $301M (-$255M)
67% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$27.1M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$7.01M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3.98M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$3.69M |
| 5 |
JP Morgan Chase
New York
|
+$3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$21.4M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$21.4M |
| 3 |
VAM
Visium Asset Management
New York
|
-$12.3M |
| 4 |
DM
Deerfield Management
New York
|
-$8.72M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.02M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
101
Acuity Investment Management
Toronto,
Ontario, Canada
| – | -$65K | -1,900 | Closed |
|
|
PAM
102
Paradigm Asset Management
New York
| – | -$64.6K | -1,900 | Closed |
|
|
U
103
UBS
Zurich,
Switzerland
| – | -$55K | -1,622 | Closed |
|
|
SFU
104
Stonehage Fleming (UK)
London,
United Kingdom
| – | -$24K | -716 | Closed |
|
|
BHMP
105
Bardin Hill Management Partners
New York
| – | -$23K | -684 | Closed |
|
|
VFA
106
Virtus Fund Advisers
Hartford,
Connecticut
| – | -$20K | -590 | Closed |
|
107
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$6K | -170 | Closed |
|
RVNC Hedge Fund Activity: Q3 2014 in Review
80 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2014, worth a combined $301M — down 46% from $556M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of RVNC and 9 opened new positions — a net loss of 18 holders — while 19 trimmed existing stakes and 40 added.
The largest buyer was Franklin Resources, adding an estimated $27.1M. The largest seller was Jennison Associates, cutting an estimated $21.4M.
- 80 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2014, down from 98 in Q2 2014.
- Funds reported $301M of Revance Therapeutics, Inc. stock for Q3 2014, down 46% quarter-over-quarter.
- 9 funds opened new Revance Therapeutics, Inc. positions in Q3 2014 and 27 closed out, a net change of -18 holders.
- The largest Revance Therapeutics, Inc. buyer in Q3 2014 was Franklin Resources, an estimated $27.1M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2014 was Jennison Associates, an estimated $21.4M sold.
Based on aggregated 13F filings for Q3 2014.